December 1, 2008
FibroGen Appoints Frank H. Valone, M.D., Chief Medical Officer

November 10, 2008
FibroGen Announces New Research on HIF-PHI and Anti-CTGF Development Programs in Chronic Kidney Disease

August 29, 2008
Toshinari Tamura, Ph.D., Joins Board of Directors of FibroGen, Inc.

January 22, 2008
FibroGen Reports New Research on Development of HIF Prolyl Hydroxylase Inhibitors Related to Endothelial Progenitor Cells, Anti-Inflammation, Cytoprotection and Erythropoiesis

2007:

November 7, 2007
FibroGen Announces New Research in HIF and CTGF Therapeutic Programs Presented at the Annual Meeting of the American Society of Nephrology

February 9, 2007
FibroGen Reports Pharmacologic Stabilization of Hypoxia-Inducible Factor (HIF) Prevents Brain Tissue Damage and Preserves Motor Function in a Preclinical Model of Transient Ischemic Stroke

2006:

November 17, 2006
FibroGen Reports Results of a Phase 1b Study of FG-3019, Therapeutic Antibody Against CTGF, in Diabetic Patients with Microalbuminuria

November 17, 2006
FibroGen Reports that FG-4539, HIF-PH Inhibitor, is Renoprotective and Improves Renal Function in Preclinical Models of Acute Kidney Injury

September 27, 2006
FibroGen and Shorenstein Properties Execute Build-to-Suit Construction and Long-term Lease for Mission Bay Property

September 13, 2006
FibroGen Appoints Melissa L. Grigorieff, Vice President of Marketing

August 22, 2006
FibroGen Awarded Grant from National Heart, Lung, and Blood Institute to Develop HIF-PH Inhibitors to Treat Sickle Cell Disease

June 22, 2006
FibroGen Announces Investigational Anti-CTGF Therapeutic, FG-3019, Reduces Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

June 12, 2006
FibroGen Reports Combinations of FG-3019 plus ACEi and FG-3019 Plus ARB Prevented and Reversed Arterial Stiffness Significantly Better than ACEi or ARB Alone in Preclinical Models of Diabetes

April 28, 2006
FibroGen Licenses Oral HIF-PH Inhibitors, Including FG-2216 and FG-4592, to Astellas for the Treatment of Anemia in Europe and Other Regions

February 17, 2006
FibroGen Reports FG-4539, HIF-PH Inhibitor, Is Neuroprotective and Significantly Reduces Brain Tissue Damage in Preclinical Model of Ischemic Stroke

. . . to 2005 press releases